Horsman J M, Thomas J, Hough R, Hancock B W
YCR Academic Unit of Clinical Oncology, Weston Park Hospital, Sheffield S10 2SJ, UK.
Int J Oncol. 2006 Jun;28(6):1571-5. doi: 10.3892/ijo.28.6.1571.
The aim of this study was to retrospectively define those patients with unequivocal primary bone lymphoma presenting to the Sheffield Lymphoma Group and document patient and tumour characteristics and management strategies, and correlate these with survival. Thirty-seven patients were documented from a total of 3148 cases of non-Hodgkin's lymphoma seen over 34 years. There were 17 males and 20 females, with a mean age of 55.4 years (range, 27-78). Pain was the most commonly presented symptom (67.5%), and the pelvis was the most frequently presented site (21.3%). Grade 2 and diffuse large B cell lymphoma comprised the majority of histologies (78.7% and 70.3%, respectively). Treatment was most often with radiotherapy alone (41.8%) or combined with CHOP-like chemotherapy (37.9%). The overall response rate was 56.7%, and 5- and 10-year survival rates were 64.5% and 49.6%, respectively. Univariate analysis showed an age of <60 years and complete response to be favourable prognostic factors. There was a trend toward better survival with combined modality therapy involving CHOP-like chemotherapy. Bone lymphoma has a better survival than other extranodal lymphomas. Younger age and complete response are favourable predictive factors. Combined modality treatment is likely to be the treatment of choice but this remains to be confirmed in large prospective multicentre studies.
本研究的目的是回顾性地确定那些就诊于谢菲尔德淋巴瘤研究组的明确原发性骨淋巴瘤患者，并记录患者及肿瘤特征和治疗策略，并将这些与生存率相关联。在34年间所见的总共3148例非霍奇金淋巴瘤病例中记录了37例患者。其中男性17例，女性20例，平均年龄55.4岁（范围27 - 78岁）。疼痛是最常见的症状（67.5%），骨盆是最常出现病变的部位（21.3%）。2级和弥漫性大B细胞淋巴瘤占组织学类型的大多数（分别为78.7%和70.3%）。治疗最常采用单纯放疗（41.8%）或联合类似CHOP方案的化疗（37.9%）。总缓解率为56.7%，5年和10年生存率分别为64.5%和49.6%。单因素分析显示年龄<60岁和完全缓解是有利的预后因素。采用类似CHOP方案化疗的综合治疗方式有生存更好的趋势。骨淋巴瘤比其他结外淋巴瘤有更好的生存率。年轻和完全缓解是有利的预测因素。综合治疗方式可能是首选治疗方法，但这仍有待大型前瞻性多中心研究证实。
